GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2012-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess whether the presence of a particular form of a gene, GABRA2, affects the functional responses of the human brain to alcohol administration and will evaluate that relationship in the context of factors known to increase the risk for future alcoholism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630

Alcoholism

COMPLETED PHASE2

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

NCT02884908

PTSD Alcohol Use Disorder

COMPLETED PHASE3

Medication Development in Alcoholism: Apremilast Versus Placebo

NCT03175549

Alcohol Use Disorder

COMPLETED PHASE2

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628

Alcohol-induced Cue-craving Alcohol Sensitivity

TERMINATED PHASE1

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

NCT00612352

Alcoholism

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur approximately 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Two session, within subjects, single blind

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Responses to alcohol

Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.

Group Type EXPERIMENTAL

Alcohol

Intervention Type OTHER

Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

Placebo

Intervention Type OTHER

Placebo (saline vehicle) infused for 2.8 hour long session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alcohol

Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

Intervention Type OTHER

Placebo

Placebo (saline vehicle) infused for 2.8 hour long session.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* European American male and females between 21-27 years of age.
* Good health as determined by medical history, physical exam, and laboratory tests.
* Females must have a negative urine pregnancy (hCG) test at the start of each study session.
* People who consume 0.10 standard drinks per week (12 g-ethanol) per liter of total body water when averaged over the preceding month, or more, OR who have consumed more than 0.10 standard drinks per liter of total body water on any one occasion in the last month.

Exclusion Criteria

* Inability to read or comprehend eighth grade English.
* Inability to hear or comprehend verbal instructions, or inability or unwillingness to cooperate with the procedures required for the study.
* Inability to resolve 2 dots, each 2 mm in diameter with centers placed 5 mm apart on a card placed 20 inches from the bridge of the nose, or the need to wear eyeglasses to do so.
* Current or prior history of any serious disease, including head trauma causing loss of consciousness, cancer, CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or alcohol or drug dependence, but not alcohol abuse or nicotine dependence.
* Positive hepatitis or HIV test at screening, provided subject consented to these tests.
* Current or prior history of alcohol-induced flushing reactions.
* Current diagnosis of Axis-I psychiatric illness.
* Positive result on urine drug screen obtained at the face-to-face interview.
* Pregnancy, as determined by urine HcG on each day of laboratory testing, or intention to become pregnant for women.
* Use of medications known to interact with alcohol within 2 weeks of the study.

Minimum Eligible Age

21 Years

Maximum Eligible Age

27 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes